01—Abstract
Summary
Summary of the 8-K filed June 24, 2024. Cited figures are marked; the original filing is the authoritative source.
On June 20, 2024, Revolution Medicines, Inc. held its 2024 annual meeting of stockholders.
As of the April 22, 2024 record date, 170,493,095 shares of common stock were outstanding and entitled to vote, including 5,560,000 contingent earn-out shares. The filing reports the results of three proposals described in the company's April 25, 2024 proxy statement. Stockholders elected three Class I directors, Elizabeth McKee Anderson, Flavia Borellini, Ph.D., and Lorence Kim, M.D., to serve until the 2027 annual meeting.
Anderson received 107,146,109 votes for and 23,367,071 withheld, Borellini received 107,339,633 for and 23,173,547 withheld, and Kim received 97,387,991 for and 33,125,189 withheld. Each nominee had 17,669,340 broker non-votes. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 148,105,275 votes for, 9,895 against, and 67,350 abstentions.
In a non-binding advisory vote, stockholders approved the compensation of the named executive officers, with 128,861,403 votes for, 1,624,748 against, 27,029 abstentions, and 17,669,340 broker non-votes. No other items were presented for stockholder approval.
02—Key points
Key Highlights
- Annual meeting held June 20, 2024; record date April 22, 2024 with 170,493,095 shares outstanding and entitled to vote, including 5,560,000 contingent earn-out shares.
- Elizabeth McKee Anderson, Flavia Borellini, Ph.D., and Lorence Kim, M.D. were elected as Class I directors to serve until the 2027 annual meeting.
- Borellini received the most votes for (107,339,633) among the director nominees; Kim received the fewest (97,387,991) and the most votes withheld (33,125,189).
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal 2024, with 148,105,275 votes for and 9,895 against.
- Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers, with 128,861,403 votes for and 1,624,748 against.
- Broker non-votes of 17,669,340 were recorded on the director election and say-on-pay proposals; none were recorded on the auditor ratification, which the filing describes as a routine proposal.
03—Questions
Frequently Asked Questions
How many shares were eligible to vote at the 2024 annual meeting?
As of the April 22, 2024 record date, 170,493,095 shares of common stock were outstanding and entitled to vote. This count includes 5,560,000 contingent earn-out shares and excludes treasury shares.
Who was elected to the board at the 2024 annual meeting?
Stockholders elected three Class I directors: Elizabeth McKee Anderson, Flavia Borellini, Ph.D., and Lorence Kim, M.D. Each will serve until the 2027 annual meeting of stockholders or until a successor is elected and qualified.
Did stockholders approve the company's auditor?
Yes. Stockholders ratified the audit committee's appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 148,105,275 votes for, 9,895 against, and 67,350 abstentions.
How did stockholders vote on executive compensation?
In a non-binding advisory vote, stockholders approved the compensation of the named executive officers as disclosed in the proxy statement. The tally was 128,861,403 votes for, 1,624,748 against, 27,029 abstentions, and 17,669,340 broker non-votes.
04—Continue